Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into the treatment and management of various toxicities associated with CAR-T therapy, including cytokine release syndrome (CRS), neurological toxicity, and cytopenias. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.